| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424780100 | Ion exchange resin | 71 |
| 20080226579 | Novel Resinate Complex of S-Clopidogrel and Production Method Thereof - The present invention is a novel resinate complex of (+)-clopidogrel optical isomer, wherein the (+)-clopidogrel isomer is bounded to a water-soluble cation exchange resin having sulfonic acid groups. The novel resinate complex has recognized some advantages in that (1) its chemical structure is stable, and (2) it can be formulated into a solid form that may provide taste-masking capabilities associated with bitter drugs (e.g., strong irritation, bitterness and sour taste), thus requiring no drink of water. | 09-18-2008 |
| 20080233073 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 09-25-2008 |
| 20080241092 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 10-02-2008 |
| 20080241093 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 10-02-2008 |
| 20090016984 | Drug for Hyperphospheremia and Its Preparative Method - This invention reports a drug for hyperphospheremia and its preparative method. The preparation includes active constituents, lanthanum polystyrene sulfonate, and excipients. The preparative method in the invention can be summarized as follows: Polystyrene sulfonic acid is obtained by treating polystyrene sulfosalt with hydrochloric acid, soaked or eluted with water soluble lanthanum-contained solution, and washed with water till its PH is neutral. Then, the lanthanum polystyrene sulfonate solution is washed till the superfluous La | 01-15-2009 |
| 20090092573 | Method of manufacturing a nicotine delivery product - A method of manufacturing a nicotine delivery product comprising nicotine and a cation exchange resin. More precisely, to a method for preparing a nicotine delivery product said method comprising (a) mixing nicotine, a cation exchange resin, an organic polyol and water to form a mixture wherein the total amount of water is from 26 to 45% by weight of the total mixture, and (b) removing water from the mixture to produce said nicotine delivery product. | 04-09-2009 |
| 20090162311 | Agent for Prevention and/or Treatment of Glomerulopathy - Provided is a novel prophylactic and/or therapeutic agent for glomerular disease wherein a pharmaceutically acceptable anion exchange resin, typified by colestimide, is an active ingredient thereof. | 06-25-2009 |
| 20090175818 | Poly(Potassium and Sodium Styrene Sulfonate) Its Manufacture and Its Uses - Antibiotic-associated diarrhea, such as that caused by | 07-09-2009 |
| 20100028290 | DISINFECTANT - A disinfectant, especially a skin disinfectant, an antiseptic agent for open wounds and a preparation for biocidal impregnation of plants, objects or materials, especially porous objects or materials containing cellulose, plastic or textile fibres, distinguishing itself by containing 10 to 99.9 mass percent of trichloroiodic(III) resin and 0.1 to 90 mass percent of an inorganic or organic active-chlorine-containing compound. | 02-04-2010 |
| 20100074858 | Novel iodinated resin manufacturing process and product - The invention provides a novel method for manufacturing iodinated resin particulates that have widespread utility as disinfectants. The invention also provides novel iodinated demand disinfectant iodinated resins that have superior properties than resins known in the art. The novel manufacturing process of the current invention is highly efficient and environmentally friendly and is conducted without the presence of water. Additionally, the manufacturing process produces iodinated resins that have better overall biological performance than resins produced by prior art methods owing to higher degrees of iodine in the manufactured resin particulates and higher degrees of uniformity of iodine content when comparing particulate to particulate. | 03-25-2010 |
| 20100104527 | TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES - The present invention is directed to methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio. | 04-29-2010 |
| 20100111891 | LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS - The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract. | 05-06-2010 |
| 20100111892 | CROSSLINKED POLYFLUOROACRYLIC ACID AND PROCESSES FOR THE PREPARATION THEREOF - The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group and being a polymerization product of at least three monomers. Pharmaceutical compositions of these polymers are useful to bind potassium in the gastrointestinal tract. | 05-06-2010 |
| 20100129308 | Polymers Functionalized with Ion-Specific Recognition Elements - Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution. | 05-27-2010 |
| 20100272668 | ANTIVIRAL SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER STRUCTURE - The present invention is to provide an antiviral substance effective for inactivating viruses, a fiber product carrying the antiviral substance, and a fiber structure. The antiviral substance comprises a polymer containing a maleic acid component as a monomer unit in its polymer chain, and is effective against an avian influenza virus. An antiviral fiber can be produced by mixing the copolymer with cellulose and spinning the resulting mixture. | 10-28-2010 |
| 20100297054 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS - The present invention relates to substituted triazole compounds of the formula (I): | 11-25-2010 |
| 20100330021 | SUBSTITUTED (THIAZOL-2-YL)-AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES - Compounds of the formula | 12-30-2010 |
| 20110038827 | ELEVATION OF THE PLASMA HDL-CHOLESTEROL LEVEL - The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein. | 02-17-2011 |
| 20110206631 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 08-25-2011 |
| 20110236340 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA - The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract. | 09-29-2011 |
| 20120087887 | Composition and Method for Arresting Blood Flow and for Forming a Persistent Microbial Barrier - A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capable, when applied in sufficient quantities, of providing a continuing and persistent antimicrobial against planktonic microorganisms and biofilms through dehydration and ion exchange with cations present in the blood and other body fluids. When the resin has a concentration of at least 26 mg/ml, it provides a >3 log reduction in biological activity of MRSA, MRSE and Pseudomonas aeruginosa. | 04-12-2012 |
| 20120093759 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds - Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described. | 04-19-2012 |
| 20120171151 | MASS SPECTROMETRIC QUANTITATION ASSAY FOR METABOLITES OF LEFLUNOMIDE - Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample. | 07-05-2012 |
| 20120251478 | Method for treatment of a glomerular disease comprising administration of anion exchange resin - Provided is a novel prophylactic and/or therapeutic agent for glomerular disease wherein a pharmaceutically acceptable anion exchange resin, typified by colestimide, is an active ingredient thereof. | 10-04-2012 |
| 20130004452 | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof - A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations. | 01-03-2013 |
| 20130095057 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE - Disclosed are compounds of formula (I): | 04-18-2013 |
| 20130177520 | TASTE MASKED DOSAGE FORMS OF BITTER TASTING ANTI-RETROVIRAL DRUGS - The present invention relates to taste masked dosage forms of bitter tasting anti-retroviral drugs comprising a complex of the said anti-retroviral drug and an ion-exchange resin and one or more of other pharmaceutically acceptable excipients. It further relates to the processes for the preparation thereof. | 07-11-2013 |
| 20130189216 | LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS - The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract. | 07-25-2013 |
| 20130272991 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 10-17-2013 |
| 20130272992 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 10-17-2013 |
| 20130309191 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE - Disclosed are compounds of formula (I): | 11-21-2013 |
| 20140105848 | POTASSIUM BINDING POLYMERS FOR TREATING HYPERTENSION AND HYPERKALEMIA - The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function. | 04-17-2014 |
| 20140205558 | SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate. | 07-24-2014 |
| 20140286891 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 09-25-2014 |
| 20150086501 | POLYMERS FUNCTIONALIZED WITH ION-SPECIFIC RECOGNITION ELEMENTS - Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution. | 03-26-2015 |
| 20150132245 | METHOD FOR DETOXIFICATION OR MEASUREMENT OF AT LEAST ONE COMPOUND OR AT LEAST ONE FLUID IN A HOST BODY - The present invention comprises a method for detoxification or measurement of the concentration of at least one compound in a host body, wherein said host body comprises a sorption material of at least one phase over a certain period of time, where sorption of said at least one compound in at least one phase of said sorption material is effected and the content of the at least one compound in said sorption material is optionally analysed. Use of a sorption material for providing an estimate of the concentration of compounds present in a host body, use of a sorption material for detoxification and sorption material for diagnostic use is also comprised in the present application. | 05-14-2015 |
| 20150306135 | ORAL PHARMACEUTICAL COMPOSITION FOR DRUGS WITH A HIGH-DOSAGE REGIMEN - The present invention relates to an oral pharmaceutical composition for drugs with a high dosage regimen, specifically, ion exchange resins and bulk-forming laxatives. Said composition comprises the combination of a liquid oily component and a texturizing agent, giving the composition good organoleptic properties that allow taking drugs with a high dosage regimen without the usual problems associated with their poor palatability. The invention also relates to a method for preparing said composition and to the use thereof for the treatment of various pathologies. Furthermore, the invention also relates to an adduct formed between a polyol and an ion exchange resin, to a method for preparing it, and to the use thereof to improve resin palatability. | 10-29-2015 |
| 20160002251 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME - The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment. | 01-07-2016 |
| 20160102074 | SUBSTITUTED AMIDE COMPOUNDS - The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. | 04-14-2016 |
| 20160175344 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA | 06-23-2016 |
| 20160184387 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Provided are non-NHE3-binding agents having activity as phosphate transport/uptake inhibitors in the gastrointestinal tract, including in the small intestine, methods for their use as therapeutic or prophylactic agents, and related methods of drug discovery. | 06-30-2016 |
| 20160193246 | POLYMERIC SYNTHETIC ANTIDOTE | 07-07-2016 |
| 424780120 | Adsorbate or treating agent contains nitrogen | 29 |
| 20080279808 | 2,3,4,5-Tetrahydroxy-6-Sulfooxy Hexanoic Acid, Pharmaceutically Acceptable Salts and Equilibrium Forms Thereof, Processes for Their Preparation, Pharmaceutical Compositions Comprising Such Compounds and Their Medical Use - The invention relates to novel compounds of general formula I wherein M represents hydrogen, or a metallic cation, preferably an alkaline metal, or alkaline-earth metal, and n is equal to 1, 2 or 3. The present invention also comprises compounds of general formula I in their equilibrium forms, including lactonic forms, their enantiomers in pure form, or in an enriched form in one of the optical isomers, racemic mixtures, diastereomers and solvates thereof. The present invention further relates to processes for the preparation of compounds of general formula I, to pharmaceutical compositions comprising compounds of general formula I as only active ingredient, or in association with other active ingredients. Another aspect of the invention is the use of compounds of general formula I for the treatment of dyslipidemia, associated, or not, to other metabolic disorders, such as glucose intolerance syndrome and type 1 or 2 diabetes mellitus, by means of isolated administration or combined with other substances. | 11-13-2008 |
| 20090004133 | Methods and compositions for phosphate binding - The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form. | 01-01-2009 |
| 20100129309 | AMINE POLYMER COMPOSITIONS - A pharmaceutical composition for treating hyperphosphatemia can include polymers derived from multi-amine monomers and multifunctional monomers, where the multifunctional monomer includes more than one electrophilic group. | 05-27-2010 |
| 20100233116 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 09-16-2010 |
| 424780130 | Oxygen or sulfur heterocycle | 2 |
| 20100055066 | Agent for prophylactic and/or therapeutic treatment of diabetes - According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided. | 03-04-2010 |
| 20140079662 | Compositions and methods for treating respiratory disorders with doxofilline - COMPOSITONS AND METHODS FOR TREATING RESPIRATORY DISORDERS WITH DOXOFILLINE. | 03-20-2014 |
| 424780140 | Nitrogen heterocycle | 6 |
| 20100021415 | COSMETIC USE OF ORGANIC RESINATES - A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to the resin. | 01-28-2010 |
| 20120244104 | NICOTINE CONTAINING FORMULATION - Disclosed is nicotine containing solid oral transmucosal dosage forms containing a therapeutically effective amount of nicotine polacrilex, citric acid monohydrate, sucrose and liquid glucose. The dosage form is preferably in the form of lozenge. | 09-27-2012 |
| 424780150 | Plural nitrogen heteroatoms or rings | 4 |
| 20100129310 | STABILIZED DESLORATADINE COMPOSITION - Stabilized desloratadine-containing pharmaceutical compositions are prepared using complexes formed by combining desloratadine and a resin in the acidic form. | 05-27-2010 |
| 20110110880 | NICOTINE LOZENGE COMPOSITIONS - The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form. | 05-12-2011 |
| 20160113868 | NICOTINE LOZENGE FORMULATION - Aspects of the present invention are directed to a nicotine lozenge for oral administration comprising: a nicotine active; at least one high viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer; and at least one low viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer. Lozenges of the present invention are more stable and less expensive than traditional lozenges. | 04-28-2016 |
| 20160136165 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders - The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence. | 05-19-2016 |
| 424780160 | Amine containing aromatic group | 17 |
| 20080253985 | Compositions for Lowering Serum Cholesterol and/or Triglycerides - The invention provides methods and compositions for treating hyperlipidemia and disorders associated with hyperlipidemia in a mammal. Compositions useful in the practice of the invention include a microsomal triglyceride transport protein inhibitor (“MTPI”) and at least two other cholesterol lowering drugs selected from the group consisting of a cholesterol absorption inhibitor (“CAI”), a HMG-CoA reductase inhibitor, a bile acid sequestrant, a fibric acid derivative, niacin, and squalene synthetase inhibitor. | 10-16-2008 |
| 20100124541 | HYDROXYADAMANTYL INHIBITORS OF DIPEPTIDYLPEPTIDASE IV - The present invention relates to new hydroxyadamantyl inhibitors of dipeptidylpeptidase IV activity, pharmaceutical compositions thereof, and methods of use thereof. | 05-20-2010 |
| 20100129311 | PHENYLALANINE AMIDE INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof. | 05-27-2010 |
| 20100239520 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 09-23-2010 |
| 20100272671 | Co-Therapy For Diabetic Conditions - Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed. | 10-28-2010 |
| 20100291020 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS - The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. | 11-18-2010 |
| 20110158932 | Methods And Compositions For The Treatment of Hyperlipidemia - Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma. Additional compositions and methods are provided which employ a berberine compound or berberine related or derivative compound in combination with a second anti-hyperlipidemia agent, or a different therapeutic agent to yield more effective treatment tools against hyperlipidemia and/or cardiovascular disease, and/or dual activity therapeutic methods and formulations useful to prevent or reduce hyperlipidemia and one or more causal or related symptoms or conditions associated with hyperlipidemia in mammalian subjects. | 06-30-2011 |
| 20110171159 | Glycoside Derivatives and Uses Thereof - This invention relates to compounds represented by formula (I): | 07-14-2011 |
| 20110243879 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 10-06-2011 |
| 20120014906 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 01-19-2012 |
| 20120014907 | USE OF SUBSTITUTED CYANOPYRROLIDINES AND COMBINATION PREPARATIONS CONTAINING THEM FOR TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES - Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantly; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier. | 01-19-2012 |
| 20120082635 | 2-AMINO-2- [8-(DIMETHYL CARBAMOYL)- 8-AZA- BICYCLO [3.2.1] OCT-3-YL]-EXO- ETHANOYL DERIVATIVES AS POTENT DPP-IV INHIBITORS - The present invention is related to novel 2-Amino-2-[8-(dimethyl carbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-ethanoyl derivatives of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. | 04-05-2012 |
| 20130171090 | METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. | 07-04-2013 |
| 20140044668 | Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs - Methods and compositions for the effect of Cholesteryl ester transfer protein (CETP) polymorphisms on mRNA splicing, statin treatment outcome, response to CETP inhibitor drugs, and myocardial infarction risk are described. | 02-13-2014 |
| 20140356314 | 3-[3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL]PHENOL RESIN COMPLEX - The present invention discloses a 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex, preferably an amorphous 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex formed by the reaction between a cation exchange resin and 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol or a pharmaceutically acceptable acid addition salt thereof. It can exhibit an in-vitro release rate of 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol from the 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex which is in accordance with the requirements of Ph. Eur. on “conventional-release dosage forms”. | 12-04-2014 |
| 20150366981 | FINGOLIMOD CONTAINING STABLE COMPOSITION - The present invention relates to a pharmaceutical composition comprising fingolimod and a weak acid cation exchange resin in the form of an ion-exchange complex and pharmaceutically acceptable 5 excipients. | 12-24-2015 |
| 20160175332 | FUMAGILLOL DERIVATIVES | 06-23-2016 |
